BioSpace News Archive

Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today reported its financial results for the year ended December 31, 2019.

Healthcare Trust of America, Inc. announced results for the quarter and year ended December 31, 2019..

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its fourth quarter and full year 2019 operational and financial results on Thursday, February 27, 2020 after the U.S. financial markets close

AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in healthcare total talent solutions, today announced its fourth quarter and full year 2019 financial results.

Atreca, Inc. announced that the first patient has been dosed in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2019.

VistaGen Therapeutics announced financial results for its fiscal year 2020 third quarter ended December 31, 2019.

Cutera, Inc. announced that it will report financial results for the fourth quarter and full-year 2019 after the market close on Wednesday, February 26, 2020.

IQVIA Holdings Inc. announced that it has agreed to purchase an aggregate of 1,000,000 shares of its common stock in a private transaction from certain of its existing stockholders.

Phio Pharmaceuticals Corp. announced the closing of its previously announced underwritten public offering of 993,633 units at a public price of $4.00 per unit and 1,006,367 pre-funded units at a public price of $3.999 per pre-funded unit, raising gross proceeds of approximately $8.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.